Dergiler / Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi / 2020 / Cilt: 11 - Sayı: 2

Design and Analysis of Recombinant Vaccine Against Clostridium Perfringens Type A and Type E

In silico design and analysis of recombinant vaccine against Clostridium perfringens Type A and Type E.

Sayfa
138–143
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: The result of this study showed that the candidate vaccine can be stimulate HLA-DRB1*0101 and other MCHII alleles.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Clostridium perfringens is a spore-forming, anaerobic, gram positive, bacteria that exist in environment, soils, foods, and in intestinal traces of humans or animals.
📊
Temel Bulgular & Veri:Results: Physicochemical study of vaccine showed that the designed vaccine is 58.33 kDa.
💡
Sonuç & Katkı:Conclusion: The result of this study showed that the candidate vaccine can be stimulate HLA-DRB1*0101 and other MCHII alleles.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Vaccine · Clostridium perfringens · B cell

Özet

Objective: Clostridium perfringens is a spore-forming, anaerobic, gram positive, bacteria that exist in environment, soils, foods, and in intestinal traces of humans or animals. However, vaccines being developed for use in animals have the potential to be developed for use in humans. This study was aimed to design and analysis of multi epitope vaccine against Clostridium perfringens type A and E. Material-Method: The B cell epitopes were predicted by IEDB and MHC II epitopes were predicted by Vaxign web server. Results: Physicochemical study of vaccine showed that the designed vaccine is 58.33 kDa. The half-life of candidate vaccine was found to be greater than 100 hours in mammalian cells, greater than 20 hours in yeast, and greater than 10 hours in Escherichia coli. The instability index of vaccine was 28.41 (<40), the aliphatic index was found to be 47.51, and the vaccine is soluble in water and is considered stable. The grand average of hydropathicity of candidate vaccine is -1.283, consequently, the vaccine is a hydrophilic protein and easily soluble in water. The result obtained from of Toxinpred and Allertop revealed that the protein don’t have tixic and allergenic effect on human and animal cells. Pepcalc and Protparam analysis showed that the vaccine doesn’t have transmembrane helix in its structure, so no expression difficulties are expected in the development of the protein from recombinant dNa technology methods. The result obtained from docking analysis proved that the vaccine has maximum affinity to HLA-DRB1*0101 with the score of -660.73. Conclusion: The result of this study showed that the candidate vaccine can be stimulate HLA-DRB1*0101 and other MCHII alleles.

Abstract

Objective: Clostridium perfringens is a spore-forming, anaerobic, gram positive, bacteria that exist in environment, soils, foods, and in intestinal traces of humans or animals. However, vaccines being developed for use in animals have the potential to be developed for use in humans. This study was aimed to design and analysis of multi epitope vaccine against Clostridium perfringens type A and E. Material-Method: The B cell epitopes were predicted by IEDB and MHC II epitopes were predicted by Vaxign web server. Results: Physicochemical study of vaccine showed that the designed vaccine is 58.33 kDa. The half-life of candidate vaccine was found to be greater than 100 hours in mammalian cells, greater than 20 hours in yeast, and greater than 10 hours in Escherichia coli. The instability index of vaccine was 28.41 (<40), the aliphatic index was found to be 47.51, and the vaccine is soluble in water and is considered stable. The grand average of hydropathicity of candidate vaccine is -1.283, consequently, the vaccine is a hydrophilic protein and easily soluble in water. The result obtained from of Toxinpred and Allertop revealed that the protein don’t have tixic and allergenic effect on human and animal cells. Pepcalc and Protparam analysis showed that the vaccine doesn’t have transmembrane helix in its structure, so no expression difficulties are expected in the development of the protein from recombinant dNa technology methods. The result obtained from docking analysis proved that the vaccine has maximum affinity to HLA-DRB1*0101 with the score of -660.73. Conclusion: The result of this study showed that the candidate vaccine can be stimulate HLA-DRB1*0101 and other MCHII alleles.

🔖

Bu Makaleye Atıf Yap

NORİZADEHTAZEKHAND, M. (2020). Design and Analysis of Recombinant Vaccine Against Clostridium Perfringens Type A and Type E. Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 11 - Sayı: 2, 138–143. https://ajindex.com/articles/360285

Kaynakça (11)

  1. Awad, M. M., Bryant, A. E., Stevens, D. L. and Rood, J. I. (1995) Virulence studies on chromosomal α‐toxin and Θ‐toxin mutants constructed by allelic exchange provide genetic evidence for the essential role of α‐toxin in Clostridium perfringens‐mediated gas gangrene. Molecular microbiology, 15, 191-202
  2. Bryant, A. E., Chen, R. Y., Nagata, Y., Wang, Y., Lee, C., Finegold, S., Guth, P. H. and Stevens, D. L. (2000) Clostridial Gas Gangrene. I. Cellular and Molecular Mechanisms of Microvascular Dysfunction Induced by Exotoxins of Clostvidium pevfvingens. The Journal of infectious diseases, 182, 799-807
  3. Dar, H. A., Zaheer, T., Shehroz, M., Ullah, N., Naz, K., Muhammad, S. A., Zhang, T. and Ali, A. (2019) Immunoinformatics-Aided Design and Evaluation of a Potential Multi-Epitope Vaccine against Klebsiella Pneumoniae. Vaccines, 7, 88
  4. Dikhit, M. R., Kumar, A., Das, S., Dehury, B., Rout, A. K., Jamal, F., Sahoo, G. C., Topno, R. K., Pandey, K. and Das, V. (2017) Identification of potential MHC Class-II-restricted epitopes derived from Leishmania donovani antigens by reverse vaccinology and evaluation of their CD4+ T-cell responsiveness against visceral leishmaniasis. Frontiers in immunology, 8, 1763
  5. Dimitrov, I., Bangov, I., Flower, D. R. and Doytchinova, I. (2014) AllerTOP v. 2—a server for in silico prediction of allergens. Journal of molecular modeling, 20, 2278
  6. Doyle, M. P. and Buchanan, R. L. (2012) Food microbiology: fundamentals and frontiers. ed. American Society for Microbiology Press
  7. Fernández Miyakawa, M. E. and Uzal, F. A. (2005) Morphologic and physiologic changes induced by Clostridium perfringens type A α toxin in the intestine of sheep. American journal of veterinary research, 66, 251-255
  8. Gupta, S., Kapoor, P., Chaudhary, K., Gautam, A., Kumar, R., Raghava, G. P. and Consortium, O. S. D. D. (2013) In silico approach for predicting toxicity of peptides and proteins. PloS one, 8, e73957
  9. Guruprasad, K., Reddy, B. B. and Pandit, M. W. (1990) Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. Protein Engineering, Design and Selection, 4, 155-161
  10. Jain, A., Tripathi, P., Shrotriya, A., Chaudhary, R. and Singh, A. (2015) In silico analysis and modeling of putative T cell epitopes for vaccine design of Toscana virus. 3 Biotech, 5, 497-503
  11. Jenssen, H. and Aspmo, S. I. (2008), in Peptide-based drug design,